Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Pneumothorax-II01:27

Pneumothorax-II

139
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
139
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

197
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
197
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Alternative Therapeutic Approaches in the Management of Gastroparesis: A Systematic Review.

Diseases (Basel, Switzerland)·2026
Same author

Transcatheter Interventional Options in Pulmonary Vein Stenosis: When to Stent?

Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual·2026
Same author

Genetic Syndromes Do Not Affect Survival but Increase Morbidity in Neonates with Symptomatic Tetralogy of Fallot.

The Journal of pediatrics·2026
Same author

Development of a lifelong core outcome set for oesophageal atresia ± tracheoesophageal fistula: the OCELOT study.

BMJ open·2026
Same author

Rome V Pediatric Upper Gastrointestinal Disorders of Gut-Brain Interaction.

Gastroenterology·2026
Same author

Critical Aortic Valve Stenosis in Infants.

Clinics in perinatology·2025

相关实验视频

Updated: Jun 24, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

对肺静脉狭窄症的干预措施

Sophia Hsien1, Usha Krishnan1, Christopher J Petit1

  • 1Division of Pediatric Cardiology, New York Presbyterian Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA.

Interventional cardiology clinics
|June 5, 2024
PubMed
概括

儿童肺静脉狭窄 (PVS) 是一种严重的疾病. 最近的干预和全身疗法改善了结果,但PVS经常复发,需要持续管理.

科学领域:

  • 儿童心脏病学 儿童心脏病学
  • 干预性肺病学 干预性肺病学
  • 罕见疾病 罕见疾病

背景情况:

  • 肺静脉狭窄 (PVS) 是一种罕见的儿科疾病,患病率和死亡率很高.
  • 从历史上看,对PVS的有效治疗方法是有限的.
  • 最近的进展表明,在管理这种具有挑战性的疾病方面有希望.

研究的目的:

  • 审查目前针对儿科肺静脉狭窄症的干预技术.
  • 讨论干预性和全身疗法的组合.
  • 在管理PVS方面分享集体经验和实践.

主要方法:

  • 审查最先进的干预技术.
  • 结合干预和全身疗法的结果分析.
  • 基于集体临床经验的讨论.

主要成果:

  • 与全身疗法相结合的干预技术显著改善了患有PVS的儿童的治疗结果.
  • 尽管最初的缓解,狭窄可靠地复发和进展.
  • 持续的管理和先进的技术至关重要.

结论:

关键词:
心脏重症监护病房的心脏重症监护病房计算机断层扫描血管图谱.遗传性心脏病是一种先天性心脏病.专利的管道是动脉动脉的.儿科的肺静脉狭窄干预措施

更多相关视频

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K

相关实验视频

Last Updated: Jun 24, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

2.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.3K
  • 综合干预和全身治疗对PVS的结果产生了显著的影响.
  • PVS的复发和进展需要持续的治疗策略.
  • 本综述强调了当前管理儿科PVS的最佳实践.